A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer. READ MORE
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.